Side effects across medicines
Medicines whose labels list chest discomfort
109 medicines have an FDA label that names chest discomfort in its boxed warning, warnings, adverse reactions, trial table, patient leaflet or Drug Facts “stop use” warning (of the labels PlainMeds reads: each medicine's quoted label and up to eight more, by route and wording). Among them, the most FAERS reports of chest discomfort name albuterol (7,451), treprostinil (2,744) and infliximab (2,605), through July 30, 2026. A label lists what its studies and reports found, and a report does not show that a medicine caused the event.
Check it at the source: the FDA FAERS public dashboard; FDA labels on DailyMed.
Which medicines' labels list chest discomfort?
Ordered by where the label names it, the boxed warning first, then by FAERS reports. A medicine whose own indications name it, because it treats it, is not counted.
| Medicine | Where a label names it | FAERS reports of chest discomfort |
|---|---|---|
| Daratumumab | warnings and precautions | none in the top 1,000 |
| Doxercalciferol | warnings and precautions (oral label) | none in the top 1,000 |
| Obiltoxaximab | warnings and precautions | none in the top 1,000 |
| Albuterol | adverse reactions (oral label) | 7,451 |
| Treprostinil | adverse reactions (respiratory (inhalation) label) | 2,744 |
| Ciclesonide | adverse reactions | 1,207 |
| Natalizumab | adverse reactions | 685 |
| Sumatriptan | adverse reactions (subcutaneous label) | 683 |
| Estradiol | adverse reactions (topical label) | 675 |
| Alemtuzumab | adverse reactions | 553 |
| Ustekinumab | adverse reactions | 514 |
| Varenicline | adverse reactions | 452 |
| Ivacaftor and lumacaftor | adverse reactions | 343 |
| Moxifloxacin | adverse reactions | 273 |
| Amikacin | adverse reactions (respiratory (inhalation) label) | 260 |
| Iohexol | adverse reactions | 248 |
| Nilotinib | adverse reactions | 238 |
| Umeclidinium and vilanterol | adverse reactions | 221 |
| Aprepitant | adverse reactions (intravenous label) | 205 |
| Lubiprostone | adverse reactions | 205 |
| Iopromide | adverse reactions | 174 |
| Ferric carboxymaltose | adverse reactions | 162 |
| Oxybutynin | adverse reactions | 160 |
| Agalsidase beta | adverse reactions | 158 |
| Regadenoson | adverse reactions | 108 |
| Terbutaline | adverse reactions (subcutaneous label) | 100 |
| Hydrochlorothiazide and lisinopril | adverse reactions | 89 |
| Abiraterone | adverse reactions | 75 |
| Levodopa | adverse reactions | 60 |
| Milnacipran | adverse reactions | 48 |
| Hydroxocobalamin | adverse reactions (intravenous label) | 45 |
| Soybean oil | adverse reactions | 45 |
| Naproxen and sumatriptan | adverse reactions | 43 |
| Acetaminophen and benzhydrocodone | adverse reactions | none in the top 1,000 |
| Adenosine | adverse reactions | none in the top 1,000 |
| Alglucosidase alfa | adverse reactions | none in the top 1,000 |
| Amifostine | adverse reactions | none in the top 1,000 |
| Avalglucosidase alfa | adverse reactions | none in the top 1,000 |
| Belzutifan | adverse reactions | none in the top 1,000 |
| Bismuth subcitrate and metronidazole and tetracycline | adverse reactions | none in the top 1,000 |
| Blinatumomab | adverse reactions | none in the top 1,000 |
| Bosutinib | adverse reactions | none in the top 1,000 |
| Calcium chloride, potassium chloride, sodium chloride and sodium lactate | adverse reactions (irrigation label) | none in the top 1,000 |
| Cilastatin and imipenem | adverse reactions | none in the top 1,000 |
| Cipaglucosidase alfa | adverse reactions | none in the top 1,000 |
| Cytarabine and daunorubicin | adverse reactions | none in the top 1,000 |
| Decitabine | adverse reactions | none in the top 1,000 |
| Dexmethylphenidate and serdexmethylphenidate | adverse reactions | none in the top 1,000 |
| Dextrose, magnesium chloride and 4 other ingredients | adverse reactions | none in the top 1,000 |
| Doxylamine and pyridoxine | adverse reactions | none in the top 1,000 |
| Gadoteridol | adverse reactions | none in the top 1,000 |
| Heparin and taurolidine | adverse reactions | none in the top 1,000 |
| Human vaccinia virus immune globulin | adverse reactions | none in the top 1,000 |
| Hydralazine and isosorbide dinitrate | adverse reactions | none in the top 1,000 |
| Imiglucerase | adverse reactions | none in the top 1,000 |
| Ivermectin | adverse reactions (oral label) | none in the top 1,000 |
| Ivosidenib | adverse reactions | none in the top 1,000 |
| Lasmiditan | adverse reactions | none in the top 1,000 |
| Magnesium chloride, potassium chloride and 3 other ingredients | adverse reactions | none in the top 1,000 |
| Meropenem and vaborbactam | adverse reactions | none in the top 1,000 |
| Nalmefene | adverse reactions (nasal label) | none in the top 1,000 |
| Nitric oxide | adverse reactions | none in the top 1,000 |
| Pafolacianine | adverse reactions | none in the top 1,000 |
| Paricalcitol | adverse reactions (intravenous label) | none in the top 1,000 |
| Patisiran | adverse reactions | none in the top 1,000 |
| Phentermine and topiramate | adverse reactions | none in the top 1,000 |
| Ponesimod | adverse reactions | none in the top 1,000 |
| Porfimer | adverse reactions | none in the top 1,000 |
| Sevoflurane | adverse reactions | none in the top 1,000 |
| Solriamfetol | adverse reactions | none in the top 1,000 |
| Sulfur hexafluoride | adverse reactions | none in the top 1,000 |
| Sutimlimab | adverse reactions | none in the top 1,000 |
| Taliglucerase alfa | adverse reactions | none in the top 1,000 |
| Tolcapone | adverse reactions | none in the top 1,000 |
| Tretinoin | adverse reactions (oral label) | none in the top 1,000 |
| Triclabendazole | adverse reactions | none in the top 1,000 |
| Ustekinumab-aekn | adverse reactions | none in the top 1,000 |
| Ustekinumab-srlf | adverse reactions | none in the top 1,000 |
| Aztreonam | trial table | 139 |
| Mannitol | trial table | 50 |
| Infliximab | patient leaflet | 2,605 |
| Adalimumab | patient leaflet | 2,257 |
| Venlafaxine | patient leaflet | 717 |
| Desvenlafaxine | patient leaflet | 206 |
| Ibrutinib | patient leaflet | 202 |
| Doxorubicin | patient leaflet | 198 |
| Pegvaliase | patient leaflet | 163 |
| Rizatriptan | patient leaflet | 145 |
| Eletriptan | patient leaflet | 121 |
| Adalimumab-aaty | patient leaflet | 86 |
| Adalimumab-fkjp | patient leaflet | 80 |
| Amivantamab | patient leaflet | 58 |
| Icosapent | patient leaflet | 44 |
| Acalabrutinib | patient leaflet | 42 |
| Adalimumab-aacf | patient leaflet | none in the top 1,000 |
| Adalimumab-adbm | patient leaflet | none in the top 1,000 |
| Adalimumab-afzb | patient leaflet | none in the top 1,000 |
| Adalimumab-ryvk | patient leaflet | none in the top 1,000 |
| Amivantamab and hyaluronidase | patient leaflet | none in the top 1,000 |
| Avelumab | patient leaflet | none in the top 1,000 |
| Axitinib | patient leaflet | none in the top 1,000 |
| Frovatriptan | patient leaflet | none in the top 1,000 |
| Meloxicam and rizatriptan | patient leaflet | none in the top 1,000 |
| Naratriptan | patient leaflet | none in the top 1,000 |
| Pirtobrutinib | patient leaflet | none in the top 1,000 |
| Telisotuzumab vedotin | patient leaflet | none in the top 1,000 |
| Zanidatamab | patient leaflet | none in the top 1,000 |
| Zanubrutinib | patient leaflet | none in the top 1,000 |
| Zenocutuzumab | patient leaflet | none in the top 1,000 |
Source: FDA drug labels via openFDA, read October 8, 2026; FAERS via openFDA, reports through July 30, 2026
Which of them have the most chest discomfort reports in FAERS?
Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; MedDRA preferred term “Chest Discomfort”
What next?
- Side effects across medicines
- every reaction on PlainMeds
- Report a side effect to the FDA
- MedWatch